13 recruiting, 5 active not recruiting, 3 completed, 1 approved for marketing. 12 Phase 1, 11 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 8, Active not recruiting 3, Enrolling by invitation 1 |
| Phase 2 | 11 | Recruiting 7, Active not recruiting 2, Completed 1, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Primary Mediastinal Large B-cell Lymphoma (PMBCL): new trials by email Literature Review of Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials Research Report on Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | Malaghan Institute of Medical Research | 60 | 2024-07-12 | 2026-08-07 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors Lifestyles Implemented-Survivorship Care Plan (LS-SCP) - Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Not applicable | Recruiting | Fondazione Italiana Linfomi - ETS | 552 | 2024-02-26 | 2026-09-11 |
| Pembro Plus CAR T-cell Therapy in R/R in PMBCL Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion - Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Recruiting | Jennifer Crombie, MD | 35 | 2023-11-15 | 2026-03-05 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | TICAROS Co., Ltd. | 98 | 2023-08-03 | 2026-03-16 |
| Primary Mediastinal Large B-cell Lymphoma With CNS Involvement Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Active not recruiting | IRCCS San Raffaele | 45 | 2022-06-30 | 2025-06-26 | |
| Bio-CAR-T BS Study Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 45 | 2022-04-26 | 2026-04-30 | |
| Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma CD30.CAR-T - Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma | Phase 1 | Active not recruiting | Tessa Therapeutics | 21 | 2021-09-08 | 2023-04-20 |
| A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Pembrolizumab - Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Phase 2 | Completed | Merck Sharp & Dohme LLC | 66 | 2021-06-07 | 2026-10-27 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients CRC01, Fludarabine, Cyclophosphamide - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Curocell Inc. | 91 | 2021-03-02 | 2026-07-01 |
| Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy - Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2021-02-18 | 2026-10-07 |
| CAR T Cell Therapy Related Cardiovascular Outcomes Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia | Completed | University College London Hospitals | 150 | 2021-01-18 | 2023-05-12 | |
| Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma LP002 - Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Phase 2 | Unknown | Taizhou HoudeAoke Biomedical Co., Ltd. | 69 | 2020-12-30 | 2020-10-23 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells - Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Recruiting | Medical College of Wisconsin | 100 | 2020-05-18 | 2026-02-23 |
Showing 20 of 24. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (17) · Lymphoma, Mantle-Cell (8) · Lymphoma, Follicular (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Non-Hodgkin (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Burkitt Lymphoma (3) · Lymphoma (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Recurrence (2) · Cardiotoxicity (1) · Cardiovascular Diseases (1) · Hodgkin Disease (1) · Leukemia (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma (17) · Lymphoma, B-Cell (14) · Lymphoma, Non-Hodgkin (13) · Hematologic Diseases (7) · Leukemia, Lymphoid (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Disease Attributes (5)
Cyclophosphamide (5) · fludarabine (5) · pembrolizumab (2) · 13-valent pneumococcal vaccine (1) · Automobiles (1) · Leukapheresis (1) · Pneumococcal Vaccines (1) · Receptors, Chimeric Antigen (1) · fludarabine phosphate (1)
Fondazione Italiana Linfomi - ETS (2) · Genmab (2) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · British Columbia Cancer Agency (1) · Curocell Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · IRCCS San Raffaele (1) · Jennifer Crombie, MD (1) · Malaghan Institute of Medical Research (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Medical College of Wisconsin (1) · Merck Sharp & Dohme LLC (1) · Paolo Corradini (1) · Poseida Therapeutics, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
United States (11) · Italy (7) · Canada (3) · South Korea (3) · China (2) · France (2) · Poland (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Netherlands (1)
Carla Minoia, MD (1) · Djordje Atanackovic, MD (1) · Frederick Locke, MD (1) · Jennifer Crombie, MD (1) · Kevin Hay, MD (1) · Laura A Johnson, PhD (1) · Matthew Frigault, MD (1) · Nirav Shah, MD (1) · Philip George, MBChB (1) · Robert Weinkove, PhD (1) · Sairah Ahmed (1) · Simon Heidegger, MD (1) · Ugo Consoli (1)
PMID 26205583, PMID 26659572, PMID 26738796, PMID 28291388, PMID 28701367, PMID 28774879, PMID 29226797, PMID 29713087, PMID 30165206, PMID 30275569, PMID 30518502, PMID 30592986, PMID 30782611, PMID 31201248, PMID 32242358, PMID 32702097, PMID 32888407, PMID 33180899, PMID 34508654, PMID 34515338, PMID 34516954, PMID 34628052, PMID 34891224, PMID 35583610, PMID 35597752, PMID 36358694, PMID 36385707, PMID 36542826, PMID 36548927, PMID 36821768, PMID 37690811, PMID 38151388, PMID 38889737, PMID 39322711, PMID 39870308, PMID 40163793, PMID 40472301, PMID 40763273, PMID 41740850, PMID 42212152, PMID 42284198, PMID 42411504, PMID 42431612, PMID 42541678
2017 (1), 2023 (1)